AnaptysBio (NASDAQ:ANAB) Issues Earnings Results, Misses Expectations By $0.82 EPS

AnaptysBio (NASDAQ:ANAB) released its earnings results on Monday. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82), Yahoo Finance reports. The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%.

AnaptysBio Trading Down 0.9 %

Shares of ANAB stock opened at $32.08 on Wednesday. The firm’s fifty day moving average price is $28.03 and its two-hundred day moving average price is $25.11. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $38.85. The firm has a market capitalization of $876.39 million, a P/E ratio of -5.22 and a beta of -0.25.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now directly owns 11,618 shares in the company, valued at $406,630. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 11,618 shares of the company’s stock, valued at approximately $406,630. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the transaction, the director now directly owns 1,950 shares in the company, valued at approximately $59,748. The disclosure for this sale can be found here. Insiders sold a total of 16,900 shares of company stock worth $484,824 in the last three months. Insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ANAB. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research note on Tuesday. SVB Leerink initiated coverage on shares of AnaptysBio in a report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 price target for the company. Wells Fargo & Company assumed coverage on AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of AnaptysBio in a report on Friday, May 10th. Finally, JPMorgan Chase & Co. upgraded AnaptysBio from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $29.00 to $69.00 in a report on Friday, July 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.89.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.